eBook: Scalable Cell-Based Immunotherapy Manufacture: A Comparison of Single-Use Agitated and Static Expansion Technologies

This study evaluates the expansion potential of stirred-tank bioreactors for autologous immunotherapy manufacture and compares that to current state-of-the-art static and wave-agitated cultures.

Read Now

Therapeutic Modalities: Business and Manufacturing Strategies Influencing Decisions to Develop One Therapy Type Rather Than Another

A panel discussion on the factors that go into the selection of therapeutic modalities including manufacturability and cost. With panelists from Cullinan Oncology, WuXi Biologics, and Mersana Therapeutics.

Read Now

eBook: Manufacturing CAR-T Cell Therapies — Insights and Challenges

For better understanding of the manufacturing difficulties, the authors analyzed technical and economic challenges encountered by CAR-T contract manufacturers and innovators. The analysis reveals that further refinement and implementation of an automated closed system could facilitate expansion of CAR-T therapies into routine cancer treatment.

Read Now

Host-Cell Protein Risk Management and Control During Bioprocess Development: A Consolidated Biotech Industry Review, Part 2

A BioPhorum Development Group has identified common HCP-related risk factors and built a template for semiquantitative risk assessment during process development based on publicly available information. They have established a common HCP risk assessment tool and mitigation strategy to guide bioprocess developers

Read Now

Using New Technologies to Compress Timelines, Increase Capacity, and Reduce Costs: Speed — Why, When, and How

In this roundtable about adopting and implementing new technologies in the biologics industry, moderator Tom Ransohoff stressed the importance of understanding drivers and risks. Panelists included Chris Love, MIT; Jorg Thommes, Bill and Melinda Gates Medical Research Institute; Geoffrey Hodge, UNUM Therapeutics; and Rajesh Beri, Lonza Pharma and Biotech.

Read Now